Neurescue’s resuscitation device nets European approval for non-shockable cardiac arrests
Not all cardiac arrests can be treated with an electric shock. In fact, most of them—about 80%—are ineligible for defibrillation. With a survival rate of about 4%, these deaths continue to number between 7 million and 9 million per year.
Neurescue has been working for over a decade to develop an easy-to-use system capable of directing oxygenated blood to the heart and brain when it’s needed most. Now, the former Fierce Medtech Fierce 15 winner has received a European approval for its smart balloon catheter, marking a major addition to the field of resuscitation.
